ARTICLE | Company News
Paion GmbH, Forest Laboratories deal
July 12, 2004 7:00 AM UTC
FRX licensed exclusive North American development and marketing rights from Paion for desmoteplase to treat stroke. FRX will fund all continuing clinical development activities in the U.S. and Canada ...